<DOC>
	<DOC>NCT00282971</DOC>
	<brief_summary>To assess the impact on glucose control by inhaled insulin in patients with type 2 diabetes who are not well controlled on 2 or more oral anti-diabetic agents</brief_summary>
	<brief_title>A Clinical Trial Assessing The Impact Of Inhaled Insulin On Glucose Control In Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>The study was terminated on Nov. 9, 2007. This study pursued scientific questions that were complementary to the wealth of data already available for Exubera. Pfizer decided to cancel new trials because of the decision to withdraw Exubera due to lack of market performance and not for safety reasons.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Diabetes mellitus type 2 Failing two or more oral antidiabetic agents Asthma, COPD Smoking</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Type 2 diabetes melllitus</keyword>
</DOC>